As per Future Market Insights, the osteoarthritis gene therapy market is forecasted to attain a valuation of US$ 7.5 billion by 2023-end. Global demand for osteoarthritis gene therapy is expected to soar at a CAGR of 7.9% to US$ 16 billion in 2033, supported by:
| Data Points | Key Statistics |
| Expected Market Value in 2023 | US$ 7.5 billion |
| Projected Market Value in 2033 | US$ 16 billion |
| Growth Rate (2023 to 2033) | 7.9% CAGR |
The demand outlook is anticipated to develop steadfast during the forecast period.
The providers of this therapy are expected to go through a high demand phase that would offer them various opportunities for progress.
The development of the osteoarthritis gene therapy market in Europe is gaining momentum, with a focus on improving patient outcomes and addressing the unmet medical needs of those suffering from osteoarthritis. The increasing prevalence of the disease, coupled with advancements in gene editing and delivery technologies, is driving growth in the field.
Pharmaceutical companies are also investing heavily in the development of new treatments, with several clinical trials underway in the region. With the increasing awareness of the potential of gene therapy to address the underlying causes of osteoarthritis, the market is expected to continue to grow in Europe in the coming years, providing new and innovative treatments for patients.
Hospitals are the most lucrative end-user of the osteoarthritis gene therapy market due to their role in delivering advanced medical treatments to patients. As the demand for effective treatments for osteoarthritis increases, hospitals are at the forefront of providing gene therapy as a potential solution. Numerous hospitals have a strong financial incentive to offer the latest treatments, as they can charge premium prices for these innovative therapies.
Osteoarthritis (OA) is one of the leading cause of disability in the western world. According to the Osteoarthritis Foundation International, the prevalence of OA is approximately 500 million people, globally.
The disease is characterized by being incurable, incurring immense treatment cost but responding very poorly to the treatment. The fact that OA is a debilitating disease and gene therapy provides a hope for treatment and pain reduction, there is a very high demand for this therapy, globally. This is one of the major driver for this market.
The presence of a large number of geriatric and target patients, as well as improved healthcare infrastructure in several countries in the Asia-Pacific region, is expected to open up market opportunities during the forecast period.
A novel approach to gene editing using the CRISPR / Ca9 system bypasses disease-causing mutations in a gene, providing treatment for single-gene-related genetic diseases such as cystic fibrosis, certain types of sickle cell anemia and other rare diseases.
The CRISPR / Ca9 system has created promising new therapies for genes that can target and correct disease-causing mutations in a gene. In this process, Cas9 - a bacterial protein - cuts DNA at a specific location where it can edit, trim the genetic sequence, or insert a new sequence before repairing the DNA.
The Osteoarthritis gene therapy market in the USA and Canada regions is expected to be slightly affected due to the COVID-19 pandemic. The demand is supposed to show slight growth due to the government investments in various R&D activities in cell based research.
Since the gene therapy can be personalized for every patient’s need, this is anticipated to drive the demand outlook in these regions.
The European region dominated osteoarthritis gene therapy market during the year 2020. This can be attributed to various reasons that contribute to the demand of this therapy such as rising prevalence of osteoarthritis cases in the region, increased geriatric population due to increased access to advanced medical care and rising obesity rates in various countries of Europe.
The key players in osteoarthritis gene therapy demand outlook are
On 19th November 2018, Mundipharma signed a multi-year agreement with Kolon Life Sciences, where they secured the exclusive rights for Invossa osteoarthritis therapy in Japan. This collaboration was intended to ensure that all the patients suffering from osteoarthritis in Japan had access to latest breakthrough treatments like Invossa.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.
The report also maps the qualitative impact of various market factors on market segments and geographies.
Explore Similar Insights
Osteoarthritis Gene Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
